|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BAZ2A |
Gene summary for BAZ2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BAZ2A | Gene ID | 11176 |
| Gene name | bromodomain adjacent to zinc finger domain 2A | |
| Gene Alias | TIP5 | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000183 | UniProtAcc | F8VU39 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11176 | BAZ2A | C43 | Human | Oral cavity | OSCC | 6.46e-19 | 4.47e-01 | 0.1704 |
| 11176 | BAZ2A | C46 | Human | Oral cavity | OSCC | 9.25e-18 | 4.06e-01 | 0.1673 |
| 11176 | BAZ2A | C51 | Human | Oral cavity | OSCC | 5.34e-20 | 7.37e-01 | 0.2674 |
| 11176 | BAZ2A | C57 | Human | Oral cavity | OSCC | 8.14e-18 | 4.80e-01 | 0.1679 |
| 11176 | BAZ2A | C06 | Human | Oral cavity | OSCC | 7.39e-04 | 9.06e-01 | 0.2699 |
| 11176 | BAZ2A | C08 | Human | Oral cavity | OSCC | 5.39e-22 | 5.24e-01 | 0.1919 |
| 11176 | BAZ2A | C09 | Human | Oral cavity | OSCC | 4.57e-08 | 3.78e-01 | 0.1431 |
| 11176 | BAZ2A | LN22 | Human | Oral cavity | OSCC | 2.84e-05 | 7.15e-01 | 0.1733 |
| 11176 | BAZ2A | LN46 | Human | Oral cavity | OSCC | 1.25e-07 | 3.34e-01 | 0.1666 |
| 11176 | BAZ2A | LP15 | Human | Oral cavity | LP | 3.83e-04 | 6.11e-01 | 0.2174 |
| 11176 | BAZ2A | LP17 | Human | Oral cavity | LP | 8.62e-03 | 5.52e-01 | 0.2349 |
| 11176 | BAZ2A | EOLP-1 | Human | Oral cavity | EOLP | 3.49e-04 | 1.53e-01 | -0.0202 |
| 11176 | BAZ2A | NEOLP-2 | Human | Oral cavity | NEOLP | 7.27e-04 | 1.71e-01 | -0.0196 |
| 11176 | BAZ2A | SYSMH1 | Human | Oral cavity | OSCC | 1.32e-15 | 4.99e-01 | 0.1127 |
| 11176 | BAZ2A | SYSMH2 | Human | Oral cavity | OSCC | 1.22e-16 | 4.57e-01 | 0.2326 |
| 11176 | BAZ2A | SYSMH3 | Human | Oral cavity | OSCC | 5.23e-19 | 5.84e-01 | 0.2442 |
| 11176 | BAZ2A | SYSMH5 | Human | Oral cavity | OSCC | 2.89e-02 | 9.58e-02 | 0.0647 |
| 11176 | BAZ2A | SYSMH6 | Human | Oral cavity | OSCC | 6.48e-05 | 1.64e-01 | 0.1275 |
| 11176 | BAZ2A | 047563_1562-all-cells | Human | Prostate | BPH | 1.53e-03 | 1.31e-02 | 0.0791 |
| 11176 | BAZ2A | Dong_P1 | Human | Prostate | Tumor | 4.06e-22 | 1.12e-01 | 0.035 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00165754 | Esophagus | ESCC | histone deacetylation | 60/8552 | 82/18723 | 3.85e-07 | 5.32e-06 | 60 |
| GO:00064765 | Esophagus | ESCC | protein deacetylation | 70/8552 | 101/18723 | 1.29e-06 | 1.58e-05 | 70 |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:00063602 | Esophagus | ESCC | transcription by RNA polymerase I | 42/8552 | 55/18723 | 3.41e-06 | 3.78e-05 | 42 |
| GO:00708973 | Esophagus | ESCC | transcription preinitiation complex assembly | 30/8552 | 36/18723 | 3.60e-06 | 3.95e-05 | 30 |
| GO:00708281 | Esophagus | ESCC | heterochromatin organization | 31/8552 | 46/18723 | 2.42e-03 | 1.06e-02 | 31 |
| GO:00063611 | Esophagus | ESCC | transcription initiation from RNA polymerase I promoter | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
| GO:0045814 | Esophagus | ESCC | negative regulation of gene expression, epigenetic | 32/8552 | 50/18723 | 6.90e-03 | 2.52e-02 | 32 |
| GO:0006304 | Esophagus | ESCC | DNA modification | 68/8552 | 120/18723 | 9.95e-03 | 3.42e-02 | 68 |
| GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
| GO:00063255 | Liver | NAFLD | chromatin organization | 64/1882 | 409/18723 | 2.31e-04 | 3.89e-03 | 64 |
| GO:0043414 | Liver | NAFLD | macromolecule methylation | 47/1882 | 316/18723 | 4.08e-03 | 3.41e-02 | 47 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BAZ2A | SNV | Missense_Mutation | rs573868102 | c.4711N>A | p.Glu1571Lys | p.E1571K | Q9UIF9 | protein_coding | deleterious(0.01) | possibly_damaging(0.812) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| BAZ2A | SNV | Missense_Mutation | novel | c.656C>A | p.Ala219Glu | p.A219E | Q9UIF9 | protein_coding | deleterious(0.01) | benign(0.06) | TCGA-A2-A0T4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD |
| BAZ2A | SNV | Missense_Mutation | rs759726101 | c.5479N>T | p.Val1827Leu | p.V1827L | Q9UIF9 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| BAZ2A | SNV | Missense_Mutation | c.4906N>A | p.Glu1636Lys | p.E1636K | Q9UIF9 | protein_coding | deleterious(0.01) | possibly_damaging(0.867) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BAZ2A | SNV | Missense_Mutation | rs200742397 | c.5366N>A | p.Arg1789Gln | p.R1789Q | Q9UIF9 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| BAZ2A | SNV | Missense_Mutation | rs781722269 | c.2376G>C | p.Lys792Asn | p.K792N | Q9UIF9 | protein_coding | deleterious(0.04) | benign(0.109) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| BAZ2A | SNV | Missense_Mutation | rs781722269 | c.2376G>C | p.Lys792Asn | p.K792N | Q9UIF9 | protein_coding | deleterious(0.04) | benign(0.109) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| BAZ2A | SNV | Missense_Mutation | rs781722269 | c.2376N>C | p.Lys792Asn | p.K792N | Q9UIF9 | protein_coding | deleterious(0.04) | benign(0.109) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| BAZ2A | SNV | Missense_Mutation | c.859N>A | p.Gln287Lys | p.Q287K | Q9UIF9 | protein_coding | tolerated(0.55) | possibly_damaging(0.9) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BAZ2A | SNV | Missense_Mutation | rs560947120 | c.3068N>A | p.Arg1023Gln | p.R1023Q | Q9UIF9 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-E2-A1L6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11176 | BAZ2A | ENZYME | inhibitor | 252166772 | ||
| 11176 | BAZ2A | ENZYME | inhibitor | 249565913 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |